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19%. To date, follow-up angiographic and IVUS volumetric analysis was performed in 17 
lesions and the results are showed in the table bellow. There were no cardiac Or drug- 
related adverse clinical events. 
PROXIMAL STENT DISTAL 
EDGE EDGE 
MLD (mm) 2.74*0.79 2.61*0.68 2.84*0.48 
Late Loss (mm) 0.47 0,52 0,19 
Restenosis Rate % (>50%DS) 5.9 5.9 0 
Lumen Volume (mm3) 33.3+11.6 115.1*46.9 35.6t8.7 
lntimal Hyperplasia Volume (mm3) 6.7 15.5 1.4 
lntimal Hyperplasia (% of volume) 16.7 11.8 3,7 
Hyperplasia Index (mmYmm) 1,3 0,97 0,2 
Conclusions: Oral Sirolimus treatment during 14 days showed to be safe without car- 
diac or drug-related adverse events. Angiographic and IVUS volumetric analysis suggest 
that adjunct oral Sirolimus decrease neointimal hyperplasia after Stem implantation in 
denovo coronary lesions 
lo:24 a.m. 
1075MP-170 Bivalirudin Reduces lschemic and Hemorrhagic 
Complications of Percutaneous Coronary Intervention: 
Pooled Data From 10 Prospective Studies in 6,134 
Patients 
Frederick Feit, John A. Bittl, A. Michael Lincoff, Derek P. Chew, Neal S. Kleiman, Lars 
Wallentin. Harvey D. White, John Omiston, Richard Robson, Philip E. Aylward, Michael 
J. Attubato, New York University School of Medicine, New York, NY, The Cleveland 
Clinic Foundation, Cleveland, OH 
Background: Bivalirudin is a thrombin-specific anticoagulant approved for use in angio- 
plasty. Recent studies have evaluated the use of bivalirudin with GP Ilb/llla inhibitors and 
stents. We combined the entire reported clinical trial experience for bivalirudin vs. hep- 
arin in percutaneous coronary intetventlon (PCI). 
Methods: Ten prospective PCI studies performed between 1993 and 2001 were 
included in the analvs~s. A Sinale data set was built usina common data fields and 
descriptions of vanables. Bivalirudin and heparin were given at a range of doses consis- 
tent with the standard of care at the time. Thienoovridines were aiven in 8 studies: GPllb/ 
I  
llla inhibitors in 6 studies. Myocardlal infarction (Ml) was generally defined as CK-MB > 
3x normal and hemorrhage as a > 3g/dl decrease in hemoglobin. 
Results: A total of 6,134 patients, median age 63 yrs, 70% male, were treated with biva- 
lirudin (n=3,277) or heparin (“~2,857). The results for the ischemic (death, MI. target ves- 
sel revascularization (TVR)) and hemorrhagic endpoints within seven days are shown in 
the table. 
Conclusions: In this analysis of IO prospective PCI trials, bivalirudin reduced the triple 
lschemic endpoint of death, MI, TVR by 24% (p=O.O03) and reduced hemorrhage by 63% 
(p<O.OOOl). Thus, bivalirudin is superior to heparin in preventing both ischemic and hem- 
orrhaglc complications in a broad population of patients undergoing PCI. 
All PC1 Trials nz6.134 
Bivalirudin (n=3,277) Heparin (n=2,857) 
n (%) n (%) 
Any event 241 (7.4) 372 (13.0) 
Death/MI/TVR 186 (5.7) 215 (7.5) 
Death/Ml 113 (3.4) 127 (4.4) 
Death 7 (0.2) 8 (0.3) 
Ml 109 (3.3) 124 (4.3) 
NR 107 (3.3) 137 (4.8) 










1075MP-171 Excessive Body Weight Does Not Increase the Risk of 
Complications Following Percutaneous Coronary 
Interventions 
Abel E. Morevra, Ajay K. Agarwala, Kenneth Khaw, Natalie Socha, Alan C. Wilson, 
UMDNJ-Roben Wood Johnson Medical School, New Brunswick, NJ 
Background: Excessive body weight (BMI) has been reported as a risk factor for compli- 
cations following percutaneous coronary interventions (PCI). However, recent significant 
technological advances in PCI have prompted a re-examination of this association to 
study the association of exceswe BMI with increased complications of PCI. 
Methods: A university hospital database of 9,537 consecutive patients undergoing PCI 
was analyzed. The International Obesity Task Force classifwtion was used. 
Results: There were no significant differences in the rates of success, emergency 
bypass surgery (CABG), transfusion, or bleeding complications between the BMI 
classes. Healthy weight patients had a higher In-hospital death rate (1.8%, p=O.O03) 
compared to the other BMI classes. After adjusting for demographic and procedural vari- 
ables with multivariate analysis, BMI had no independent association with PCI complaa- 
tions. 
Conclusion: In contrast with previous reports, excessive BMI (>35) was not found to be 
a risk factor for death or major complications of PCI. Although bleeding complications 
were higher among patients with higher BMI, the incidence rate was lower than previ- 
ously reported. We conclude that these favorable results may be due to new technolo- 
gies and improved anticoagulation approaches. 
PC1 Outcomes by BMI Class 
Healthy Overweig Obese 1 Obese Obese P 
18.5to ht 30to 2 3 Value 
<25 25 to ~30 <35 35 > 40 
to<40 
N 2,259 4,188 2,049 739 302 - 
Success Rate, % 96 96 96 96 95 NS 
Death, % 1.8 1.0 0.7 0.8 0.7 0.003 
Emergency CABG, % 1.1 0.7 1.2 0.8 1.5 NS 
Bleeding Complication, 1.9 0.8 1.4 1.6 2.6 NS 
% 
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1075MP-172 Kinetics of Intravenously Administered Dalteparin 
Chad C. Schoolev Jerry H. Gilbert, Mary Harlan, Arthur Bracey, Stephanie Coulter, 
James M. Wilson, Baylor College of Medicine, Houston, TX, Texas Heart Institute, 
Houston, TX 
Background: Outcomes using low molecular weight heparins for unstable angina and 
myccardial infarction have stimulated interest in their use during percutaneous coronary 
intewention (PCI). To define drug-dose response and clearance, we measured the anti- 
Xa activity at fixed time points after IV bolus dosing of dalteparin. 
Methods:20 medication-free volunteers (10 male, 10 female) with normal renal function 
were treated at 2 week intervals with each of 3 dalteparin doses (40, 60, and 80 IU/kg). 
Using a peripheral IV catheter, anti-Xa and anti-lla activities were measured at baseline, 
5, 15. 30, 45, 60, 240. and 480 minutes after the IV administration of dalteparin. Single 
exponential modeling was used to calculate the effective half-life (r1,28) for indivtduals 
and examine the effect of dose. The simplified MDRD formula was used to calculate 
glomerular filtration rate (GFR). 
FteeuI1B: Subjects had a mean age of 35 *4 years and mean weight of 77 +lOkg with 
GFR of 92*15 ml/min. The peak anti-Xa and anti-lla activities, T,,,. of anti-Xa activity 
after a single administration, terminal half-life of anti-Xa activity, and clearance values 
are listed below. The volume of distribution (Vd) was 41 210 ml/kg. The TIiPe was similar 
for 40 and 60 IU/kg. but was longer after a dose of 80 IUikg (p=O.O09). There was no cor- 
relation between T,i2. and GFR. 
Conclusiorr The pharmacokinetics of dalteparin I” normal individuals are described. 
These results will assist in the design of trials of dalteparin anticoagulation during PCI. 
Anti-Xa Activity Effective Tl/Z Terminal Tl12 Clearance 
(U/ml) (min) (min) (mllmin) 
40 1u/kg 1.07 64 107 25 
60 IUlkg 1.53 65 103 23 
80 IU/kg 1.83 82 128 29 
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1076-l 84 Left Ventricular Function in the Stent or Surgery Trial 
One Year After Randomization to Coronary Artery 
Bypass Graft Surgery or Stent Percutaneous Coronary 
Intervention 
Georae Koutroulis Marina Flitsou, Jean Booth, Tim Clayton, Rod H. Stables, Fiona 
Nugara, Petros Nihoyannopoulos. Hammersmith Hospital, NHLI, ICSM. London, United 
Kingdom, Royal Brompton Hospital, London, United Kingdom 
Background: In the Stem or Surgery study, we prospectively randomlsed 500 pattents to 
coronary artery bypass graft surgery (CABG) and 488 patients to stenting percutaneous 
coronary intervention (PCI), for optlmal revascularisation. We hypothesised that left ven- 
tricular (LV) function at 1 year post procedure wll be the same, regardless the initial 
treatment allocation. 
Methods: Global LV function was assessed by eJection fraction (EF, biplane modified 
Simpson’s rule), and reglonal LV function by the wall motion score index (WMSI, Ameri- 
can Society of Echocardiography), using echocardiography. Echocardiographic studies 
were analysed blindly at a core laboratory Primary outcome was a comparison of WMSI 
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and EF at one year between the two groups. The results are expressed as mean d SD. 
Results: Df the 968 patients randomised, 972 (96.4%) were alive at one year. In the sur- 
viving patients 764 (79%) had available WMSI calculations and 51.5 (53%) had EF mea- 
sured at one year. The WMSI in the CABG group (n=363) was 1.3 f 0.4, compared with 
1.2 * 0.4 in PCI group (n=361), (PcO.46, t-test). The EF in the CABG group (n=245) was 
54.6 f 9.6, compared with 55.3 f 9.3 in PCI group (n=270), difference = 0.5, 95% Cl -1 .I 
to 2.1, (P=O.55. t-test). Compared with the pre procedural values both groups showed a 
similar change in WMSI and EF. The WMSI was greater at 12 months: CABG group 1 .19 
versus 1.27, (mean difference 0.08, 95% Cl 0.04 to 0.11, pcO.001, Wilcoxon signed rank 
test), PCI group 1.19 versus 1.26 (mean difference 0.07, 95% Cl 0.03 to 0.10, p=O.OOl). 
EF was lower in both groups: CABG group 57.5 versus 54.9, (mean difference -2.7, 95% 
Cl -4.0 to -1.4, pcO.001, Wilcoxon signed rank test), in the PCI group 56.7 versus 54.9 
(mean difference -1.9, 95% Cl -2.9 to -0.6. p=O.OOl). 
Conclusions: No difference was observed in the Stent or Surgery study at one year, in LV 
function in patients treated with PCI or CABG. At one year there has been a minor 
decline in global and regional function which may be attributable to the occurrence of fac- 
tors which affect the cardiac function. 
1076-l 85 Final Angiographic and Clinical Results of the Latin 
America Small Vessel Randomized Study (LASMAL 
Trial) 
Alfred0 E. Rodriguez Msximo J. Rodriguez Alemparte, Carlos Fernandez Pereira, 
Alberlo Samoaolesi. Ronald0 Loures Buena. Carlos Rubio. Cesar F. Viao. Anael 
Obregon S&o& on behalf of Biodivysio Investigators, Otsmendi Hospital; Bu&os Aires, 
Argentina, Adrogue Medical Institute, Buenos Aires, Argentina 
BACKGROUND: Glycoprotein llbillla receptor inhibitors (GPI) reduce peri-procedural 
ischemic events in pts undergoing PCI. The optimal timing of blood draw(s) to detect CK- 
MB elevations after PCI is not well established, and less is known about their clinical pre- 
dictors. METHODS: In the TARGET trial, 4609 patients undergoing PCI were random- 
ized to abcixlmab vs tirofiban. CK-MB values were determined every 6 hrs. Timing of MB 
elevations, correlation with symptoms, and its predictors were evaluated from 4329 pts. 
RESULTS: Enzymatic infarcts (Ml, single MB value 23X or a 50% rise above abnormal 
baseline) were seen in 5.9% of pts, of whom 93.9% were reportedly asymptomatic. Only 
1.0% of pts had Q-wave infarctions after PCI, of whom l/4 had peri-PCI symptoms. In 
contrast, 67% of pts with reported symptoms after PCI had enzymatic or Q-wave infarcts. 
Table shows detection rates of Ml at each time point. In a logistic regression model, 
acute coronary syndrome (ACS). heparin use, and increasing age. but not diabetes, 
were independent predictors of peri-PCI Ml. Pre-PCI clopidogrel use was an independent 
predictor for lower rates of Ml (OR=0.57, CL [0.36-0.651). CONCLUSIONS: In pts under- 
going PCI, using GPI and contemporary stems, at least 3 blood samples within 24 hours 
are required for optimal detection of most Ml. An 16-hr sample has the best detection 
rate as a single time point. While ACS is associated with high risk of MI. pre-PCI clopi- 
dogrel therapy may have a significant cardioprotective effect in limiting CK-MB rise. 
Background: There were a conflictive data about the role of stems preventing restenosis 
in small coronary arteries. 
Methods: Between March lo December 2001,246 patients with severe stenosis in small 
native coronary artery (~2.9 mm) and clinical indication of myocardial revascularization 
were randomized in 15 centers of Latinamerica, 124 were randomized to stent and 122 
to PTCA In order to validate the reference diameter (RD) of the vessel , a comparative 
analysis between quantitative coronary angiography @CA) and Intravascular Ultrasound 
was perform. The end point of the study was lo compare angiographic binary restenosis, 
minimal luminal diameter (MLD). net gain, target vessel revascularization (TVR) and 
freedom from maior adverse cardiovascular events (MACE) at six months of follow UP, 
In conclusion: The results of the PIXEL study will help lo determine the role of direct 
stenting in small vessels. This knowledge might prove to be of great interest in the forth- 
coming era of drug eluting stents. 
1076-l 87 Timing and Risk Factors for Enzymatic Myocardial 
Infarctions in Patients Undergoing Percutaneous 
Intervention: Insights From TARGET 
H. Mehrdad Sadeahi, Cindy L. Grines, David J. Molitemo, Jennifer White. Howard 
Herrmann, Eric A. Powers, David J. Cohen, Michel E. Bertrand, Franz-Josef Neumann, 
Peter M. DiBattiste, Gregg W. Stone, Eric J. Topol, William Beaumont Hospital, Royal 
Oak, MI, The Cleveland Clinic Foundation. Cleveland, OH 
Timing of MB elevations 
6-hr 12-hr 16-hr 24.hr add’1 sample 
between both re&cularization strategies. 
Results: Both groups had similar clinical demographics and angiographic characteris- CK-MB>3X 5.6% 23.5% 47.0% 16.9% 4.6% 
tics. 
After randomization in the PTCA group. 16% crossed over to stents during the initial pro- 
cedure. Intravascular Ultrasound showed a RD in stent and PTCA of 2.6 and 2.76 mm 
respectively (ns). At 30 days patients in stent arm had less incidence of MACE than 
those included in PTCA (2.4% vs 9.6% respectively p=O.O45) Six months follow up 
anglogram was obtained in 91% of patients. 
Six months QCA and Clinical Data PTCA (122 ) Stent (124) p 
RD (mm) 2.47 +0.23 2.5 i 0.20 0.246 
MLD Post (mm) 2.1 io.30 2.32 0.25 0.0002 
MLD Follow up(mm) 1.53 2 0.67 1.76 + 0.67 0.013 
Net Gain (mm) 0.61 + 0.69 1.11 ?; 0.66 0.002 
Restenosis (%) 29 19 0.118 
TVR (%) 16 14.5 0.568 
MACE (“‘0) 27 16.9 0.078 
Conclusions: An initial strategy with stems at long term follow up achieved better MLD 
and net gain than those initially treated with PTCA. Angiographic restenosis and MACE 
showed a trend to be low with stent therapy. 
1076-l 86 Results of the PIXEL Study: Randomized Multlcenter 
Trial Comparing Direct and Conventional Predilation 
Stenting in Small Vessels 
1076-188 Acute and Late Outcome After Directional Coronary 
Atherectomy Plus Stenting Versus Stenting Alone in 
True Bifurcation Lesions 
Alaide Chisffo, Francesco Liistro, Goran Stankovic, Flavio Airoldi, MaIteo Montorfano, 
Carlo Di Mario, Davide Tavano, Antonio Colombo, San Raffaele Hospital, Milan, Italy, 
EM0 Centro Cuore Columbus Hospital. Milan, Italy 
Background: The aim of this study was to assess acute and late outcome following 
treatment of true bifurcation lesions with Directional Coronary Atherectomy (DCA) plus 
stenting (DCA group) compared to stem alone (Stent group). Methods and Results 68 
lesions in DCA group and 332 lesions in Stent group were analyzed. Baseline clinical 
and angiographic characteristics were well matched. Reference diameters in main 
branch (MB) and side branch (SB) were similar in two groups (3.1+0.5 vs. 3.020.5 and 
2.4+0.5 vs. 2.4t0.5, p=NS). Bigger minimal lumen diameter (MLD) post-procedure and 
at follow-up was achieved in DCA group (table). Binary restenosis rate (MB 17% vs 34%, 
p=O.O6 and SB 23.5% vs 41%, p=O.O9) was lower in DCA group. There was no differ- 
ence in rate of in-hospital major adverse cardiac events (MACE, i.e. death, non-Q and Q- 
wave myocardial infarction (Ml), need of revascularization) between two groups (9% 
vs.9.6%; p=NS). At 20+16 months f-up MACE rate was lower in DCA group 
(13.6%vs.32.2%; p=rJ.O2). In DCA group there were no deaths, Ml or CABG and in Stent 
group 4 pts died, 7 had Ml and 3 underwent CABG. Repeat PTCA rate was similar 
(13.6% vs. 24.8%, p=NS). Conclusions: DCA plus stenting in bifurcation lesions is not 
associated with an increased incidence of in-hospital MACE and results in improved clin- 
ical and angiographic outcome. 
Euloaio Garcia Antonio Machado, Javier Goicolea, Christian Homsy. On behalf of the 
PIXEL study investigators. Hospital Gregorio Maranon, Madrid, Spain 
Background: Coronary stenting has been established the preferred form of percutane- 
ovs revascularizarion in vessels 2 3.0 mm in diameter, accounting for more than 60% of 
the procedures, half of those performed without prior balloon pro-dilation. Trials trying to 
establish the role of stenting in small vessels have offered contradictory results and feasi- 
bility and safety of direct stenting in < 3.0 mm vessels has not been tested. 
Variables DCA Stent P value 
MB MLD After procedure 3.19+0.56 2.91+ 0.57 0.006 
MB MLD follow-up 2.0+ 1.1 i .6* 0.8 0.05 
MB Late loss 0.90t 1.2 i 23 0.8 0.1 
SB MLD After procedure 2.2+ 0.5 2.01* 0.7 0.2 
Objective and design of the study: The primary objective of the study is to demon- SB MLD follow-up 1.4* 0.7 1.2* 0.7 0.1 
strate the medium term efficacy of a no pre-dilatation strategy for elective stent implanta- SB Late loss 0.6* 0.6 o.az 0.7 0.4 
tion in native coronary arteries t 2.2mm and ~2.7 mm in diameter by on line QCA. The 
study is a prospective, randomized trial of 350 patients recruited by 26 hospitals from 
Europe, South America, India and New Zealand. The stent used was specially designed 1076-189 - 
Clinical and Angiographic Effects of Directional 
for small vessels ( Pixel stent ).The patients were centrally randomized 1:l to stent Atherectomy In De Novo Coronary Artery Lesions 
implantation with and without pre-dilation. Enrollment started in June 2001 and was corn- Located at the Ostium of the Left Anterior Descending 
pleted in August 2002. Mean patient age was 64 years; 176 patients were randomized to Artery 
pre-dilation and 174 to direct stenting. 
Endpoints: The primary endpoint is procedure success in the no pre-dilation group : Flavio Airoldi, Carlo Di Mario, Carlo Briguon’, Goran Stankovic, Alaide Chieffo, Maneo 
attainment of final result of ~30% in stent residual stenosis in the absence of MACE at 30 
Montorfano, Davide Tavano. Antonio Colombo, San Raffaele Hospital. Milan, Italy. Emo 
days. Secondary endpoints include : Acute success, procedural and fluoro time; Angio- Centro Cuore Columbus, Milan, Italy 
graphic restenosis , target site rsvascularization and target vessel failure at 6 months; Lesions located at the ostium of the left descending anterior artery (LAD) sre considered 
MACE at 6 months. Clinical and angiographic data post procedure and at follow up will an ideal target for directional atherectomy (DCA). Methods: we did a matched compari- 
be evaluated by independent corelabs. son of the immediate and mid term results of a series of 117 consecutive patients with 
